- Owner of SYNDROS®(dronabinol), the only US-based FDA approved CII Tetrahydrocannabinol (THC), a liquid cannabinoid used in adults to treat: Chemotherapy Induced Nausea and Vomiting (CINV) associated in adult patients who have failed to respond adequately to conventional antiemetic treatments; and Anorexia associated with weight loss in adult patients with Acquired Immune Deficiency Syndrome (AIDS)
- 83,000 square foot manufacturing facility in Texas is FDA registered and licensed by the U.S. DEA to manufacture Schedule I to III controlled substances in a cGMP facility, with a DEA-exemption permit to export globally
- Five FDA-registered Investigational New Drugs
- Seminal patents in organic and synthetic cannabinoids
- Pending license approval to manufacture psychedelic pharmaceuticals
Why Monro Shares Are Sliding Today
Monro Inc (NASDAQ:MNRO) reported fourth-quarter FY22 sales growth of 7.4% year-on-year, to $328 million, beating the consensus of $324.66 million. The…
